http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Apr 2026 07:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html <ul class="bwlistdisc"> <li> Bosaya™ and Vevzuo™ (both denosumab products) now approved by Health Canada </li> <li> Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer </li> </ul> <p> TORONTO &amp; BENGALURU, India--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for <b>Bosaya™ (denosumab)</b>, a biosimilar to Prolia®<i>,</i> and <b>Vezuo™ (denosumab)</b>, a biosimilar to Xgeva®<i>, </i>on April 3, 2026. Both biosimilars were approved in the most common presentations: <b>BOSAYA, </b>as a 60 mg/mL injection http://www.streetinsider.com/Press+Releases/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html Tue, 21 Apr 2026 07:05:00 -0400 532523 A.17150087 A.25841868 BIOCON O.01260902 O.26741422 O.49223070 http://www.streetinsider.com/Press+Releases/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html <ul class="bwlistdisc"> <li> Bosaya™ and Vevzuo™ (both denosumab products) now approved by Health Canada </li> <li> Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer </li> </ul> <p> TORONTO &amp; BENGALURU, India--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for <b>Bosaya™ (denosumab)</b>, a biosimilar to Prolia®<i>,</i> and <b>Vezuo™ (denosumab)</b>, a biosimilar to Xgeva®<i>, </i>on April 3, 2026. Both biosimilars were approved in the most common presentations: <b>BOSAYA, </b>as a 60 mg/mL injection http://www.streetinsider.com/Press+Releases/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html Tue, 21 Apr 2026 07:05:00 -0400 532523 A.17150087 A.25841868 BIOCON O.01260902 O.26741422 O.49223070 http://www.streetinsider.com/Press+Releases/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html <ul class="bwlistdisc"> <li> Bosaya™ and Vevzuo™ (both denosumab products) now approved by Health Canada </li> <li> Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer </li> </ul> <p> TORONTO &amp; BENGALURU, India--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for <b>Bosaya™ (denosumab)</b>, a biosimilar to Prolia®<i>,</i> and <b>Vezuo™ (denosumab)</b>, a biosimilar to Xgeva®<i>, </i>on April 3, 2026. Both biosimilars were approved in the most common presentations: <b>BOSAYA, </b>as a 60 mg/mL injection http://www.streetinsider.com/Press+Releases/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html Tue, 21 Apr 2026 07:05:00 -0400 532523 A.17150087 A.25841868 BIOCON O.01260902 O.26741422 O.49223070 http://www.streetinsider.com/Press+Releases/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html <ul class="bwlistdisc"> <li> Bosaya™ and Vevzuo™ (both denosumab products) now approved by Health Canada </li> <li> Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer </li> </ul> <p> TORONTO &amp; BENGALURU, India--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for <b>Bosaya™ (denosumab)</b>, a biosimilar to Prolia®<i>,</i> and <b>Vezuo™ (denosumab)</b>, a biosimilar to Xgeva®<i>, </i>on April 3, 2026. Both biosimilars were approved in the most common presentations: <b>BOSAYA, </b>as a 60 mg/mL injection http://www.streetinsider.com/Press+Releases/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html Tue, 21 Apr 2026 07:05:00 -0400 532523 A.17150087 A.25841868 BIOCON O.01260902 O.26741422 O.49223070 http://www.streetinsider.com/Press+Releases/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html <ul class="bwlistdisc"> <li> Bosaya™ and Vevzuo™ (both denosumab products) now approved by Health Canada </li> <li> Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer </li> </ul> <p> TORONTO &amp; BENGALURU, India--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for <b>Bosaya™ (denosumab)</b>, a biosimilar to Prolia®<i>,</i> and <b>Vezuo™ (denosumab)</b>, a biosimilar to Xgeva®<i>, </i>on April 3, 2026. Both biosimilars were approved in the most common presentations: <b>BOSAYA, </b>as a 60 mg/mL injection http://www.streetinsider.com/Press+Releases/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html Tue, 21 Apr 2026 07:05:00 -0400 532523 A.17150087 A.25841868 BIOCON O.01260902 O.26741422 O.49223070 http://www.streetinsider.com/Press+Releases/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html <ul class="bwlistdisc"> <li> Bosaya™ and Vevzuo™ (both denosumab products) now approved by Health Canada </li> <li> Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer </li> </ul> <p> TORONTO &amp; BENGALURU, India--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for <b>Bosaya™ (denosumab)</b>, a biosimilar to Prolia®<i>,</i> and <b>Vezuo™ (denosumab)</b>, a biosimilar to Xgeva®<i>, </i>on April 3, 2026. Both biosimilars were approved in the most common presentations: <b>BOSAYA, </b>as a 60 mg/mL injection http://www.streetinsider.com/Press+Releases/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html Tue, 21 Apr 2026 07:05:00 -0400 532523 A.17150087 A.25841868 BIOCON O.01260902 O.26741422 O.49223070 http://www.streetinsider.com/Press+Releases/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html <ul class="bwlistdisc"> <li> Bosaya™ and Vevzuo™ (both denosumab products) now approved by Health Canada </li> <li> Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer </li> </ul> <p> TORONTO &amp; BENGALURU, India--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for <b>Bosaya™ (denosumab)</b>, a biosimilar to Prolia®<i>,</i> and <b>Vezuo™ (denosumab)</b>, a biosimilar to Xgeva®<i>, </i>on April 3, 2026. Both biosimilars were approved in the most common presentations: <b>BOSAYA, </b>as a 60 mg/mL injection http://www.streetinsider.com/Press+Releases/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html Tue, 21 Apr 2026 07:05:00 -0400 532523 A.17150087 A.25841868 BIOCON O.01260902 O.26741422 O.49223070 http://www.streetinsider.com/Business+Wire/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html <ul class="bwlistdisc"> <li> Bosaya™ and Vevzuo™ (both denosumab products) now approved by Health Canada </li> <li> Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer </li> </ul> <p> TORONTO &amp; BENGALURU, India--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for <b>Bosaya™ (denosumab)</b>, a biosimilar to Prolia®<i>,</i> and <b>Vezuo™ (denosumab)</b>, a biosimilar to Xgeva®<i>, </i>on April 3, 2026. Both biosimilars were approved in the most common presentations: <b>BOSAYA, </b>as a 60 mg/mL injection http://www.streetinsider.com/Business+Wire/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html Tue, 21 Apr 2026 07:05:00 -0400 532523 A.17150087 A.25841868 BIOCON O.01260902 O.26741422 O.49223070 http://www.streetinsider.com/Business+Wire/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html <ul class="bwlistdisc"> <li> Bosaya™ and Vevzuo™ (both denosumab products) now approved by Health Canada </li> <li> Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer </li> </ul> <p> TORONTO &amp; BENGALURU, India--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for <b>Bosaya™ (denosumab)</b>, a biosimilar to Prolia®<i>,</i> and <b>Vezuo™ (denosumab)</b>, a biosimilar to Xgeva®<i>, </i>on April 3, 2026. Both biosimilars were approved in the most common presentations: <b>BOSAYA, </b>as a 60 mg/mL injection http://www.streetinsider.com/Business+Wire/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html Tue, 21 Apr 2026 07:05:00 -0400 532523 A.17150087 A.25841868 BIOCON O.01260902 O.26741422 O.49223070 http://www.streetinsider.com/Business+Wire/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html <ul class="bwlistdisc"> <li> Bosaya™ and Vevzuo™ (both denosumab products) now approved by Health Canada </li> <li> Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer </li> </ul> <p> TORONTO &amp; BENGALURU, India--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for <b>Bosaya™ (denosumab)</b>, a biosimilar to Prolia®<i>,</i> and <b>Vezuo™ (denosumab)</b>, a biosimilar to Xgeva®<i>, </i>on April 3, 2026. Both biosimilars were approved in the most common presentations: <b>BOSAYA, </b>as a 60 mg/mL injection http://www.streetinsider.com/Business+Wire/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html Tue, 21 Apr 2026 07:05:00 -0400 532523 A.17150087 A.25841868 BIOCON O.01260902 O.26741422 O.49223070 http://www.streetinsider.com/Business+Wire/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html <ul class="bwlistdisc"> <li> Bosaya™ and Vevzuo™ (both denosumab products) now approved by Health Canada </li> <li> Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer </li> </ul> <p> TORONTO &amp; BENGALURU, India--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for <b>Bosaya™ (denosumab)</b>, a biosimilar to Prolia®<i>,</i> and <b>Vezuo™ (denosumab)</b>, a biosimilar to Xgeva®<i>, </i>on April 3, 2026. Both biosimilars were approved in the most common presentations: <b>BOSAYA, </b>as a 60 mg/mL injection http://www.streetinsider.com/Business+Wire/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html Tue, 21 Apr 2026 07:05:00 -0400 532523 A.17150087 A.25841868 BIOCON O.01260902 O.26741422 O.49223070 http://www.streetinsider.com/Business+Wire/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html <ul class="bwlistdisc"> <li> Bosaya™ and Vevzuo™ (both denosumab products) now approved by Health Canada </li> <li> Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer </li> </ul> <p> TORONTO &amp; BENGALURU, India--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for <b>Bosaya™ (denosumab)</b>, a biosimilar to Prolia®<i>,</i> and <b>Vezuo™ (denosumab)</b>, a biosimilar to Xgeva®<i>, </i>on April 3, 2026. Both biosimilars were approved in the most common presentations: <b>BOSAYA, </b>as a 60 mg/mL injection http://www.streetinsider.com/Business+Wire/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html Tue, 21 Apr 2026 07:05:00 -0400 532523 A.17150087 A.25841868 BIOCON O.01260902 O.26741422 O.49223070 http://www.streetinsider.com/Business+Wire/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html <ul class="bwlistdisc"> <li> Bosaya™ and Vevzuo™ (both denosumab products) now approved by Health Canada </li> <li> Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer </li> </ul> <p> TORONTO &amp; BENGALURU, India--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for <b>Bosaya™ (denosumab)</b>, a biosimilar to Prolia®<i>,</i> and <b>Vezuo™ (denosumab)</b>, a biosimilar to Xgeva®<i>, </i>on April 3, 2026. Both biosimilars were approved in the most common presentations: <b>BOSAYA, </b>as a 60 mg/mL injection http://www.streetinsider.com/Business+Wire/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html Tue, 21 Apr 2026 07:05:00 -0400 532523 A.17150087 A.25841868 BIOCON O.01260902 O.26741422 O.49223070 http://www.streetinsider.com/Business+Wire/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html <ul class="bwlistdisc"> <li> Bosaya™ and Vevzuo™ (both denosumab products) now approved by Health Canada </li> <li> Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer </li> </ul> <p> TORONTO &amp; BENGALURU, India--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for <b>Bosaya™ (denosumab)</b>, a biosimilar to Prolia®<i>,</i> and <b>Vezuo™ (denosumab)</b>, a biosimilar to Xgeva®<i>, </i>on April 3, 2026. Both biosimilars were approved in the most common presentations: <b>BOSAYA, </b>as a 60 mg/mL injection http://www.streetinsider.com/Business+Wire/Biocon+Receives+Health+Canada+Approval+of+Bosaya%E2%84%A2+%28Denosumab%29+and+Vevzuo%E2%84%A2+%28Denosumab%29%2C+Biosimilars+to+Prolia%C2%AE+and+Xgeva%C2%AE/26339810.html Tue, 21 Apr 2026 07:05:00 -0400 532523 A.17150087 A.25841868 BIOCON O.01260902 O.26741422 O.49223070 http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html <p>Biocon Limited (BSE: 532523, NSE: BIOCON) announced the commercial launch of two denosumab biosimilar products in the United States. The company launched Bosaya and Aukelso, both denosumab-kyqq products, following U.S. Food and Drug Administration approval in September 2025 with interchangeable designation.</p> <p>Bosaya serves as a biosimilar to Prolia for treating osteoporosis, while Aukelso functions as a biosimilar to Xgeva for bone complications associated with cancer. Both products are available nationwide through specialty pharmacies and healthcare providers by prescription.</p> <p>The interchangeable designation allows pharmacy-level substitution in accordance with state laws. Denosumab products generated approximately $5 billion in U.S. sales in 2024, according to http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html Tue, 07 Apr 2026 09:31:06 -0400 532523 A.06822034 A.25841868 A.30142833 BIOCON O.00003102 O.01260902 O.20026344 O.26741422 http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html <p>Biocon Limited (BSE: 532523, NSE: BIOCON) announced the commercial launch of two denosumab biosimilar products in the United States. The company launched Bosaya and Aukelso, both denosumab-kyqq products, following U.S. Food and Drug Administration approval in September 2025 with interchangeable designation.</p> <p>Bosaya serves as a biosimilar to Prolia for treating osteoporosis, while Aukelso functions as a biosimilar to Xgeva for bone complications associated with cancer. Both products are available nationwide through specialty pharmacies and healthcare providers by prescription.</p> <p>The interchangeable designation allows pharmacy-level substitution in accordance with state laws. Denosumab products generated approximately $5 billion in U.S. sales in 2024, according to http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html Tue, 07 Apr 2026 09:31:06 -0400 532523 A.06822034 A.25841868 A.30142833 BIOCON O.00003102 O.01260902 O.20026344 O.26741422 http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html <p>Biocon Limited (BSE: 532523, NSE: BIOCON) announced the commercial launch of two denosumab biosimilar products in the United States. The company launched Bosaya and Aukelso, both denosumab-kyqq products, following U.S. Food and Drug Administration approval in September 2025 with interchangeable designation.</p> <p>Bosaya serves as a biosimilar to Prolia for treating osteoporosis, while Aukelso functions as a biosimilar to Xgeva for bone complications associated with cancer. Both products are available nationwide through specialty pharmacies and healthcare providers by prescription.</p> <p>The interchangeable designation allows pharmacy-level substitution in accordance with state laws. Denosumab products generated approximately $5 billion in U.S. sales in 2024, according to http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html Tue, 07 Apr 2026 09:31:06 -0400 532523 A.06822034 A.25841868 A.30142833 BIOCON O.00003102 O.01260902 O.20026344 O.26741422 http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html <p>Biocon Limited (BSE: 532523, NSE: BIOCON) announced the commercial launch of two denosumab biosimilar products in the United States. The company launched Bosaya and Aukelso, both denosumab-kyqq products, following U.S. Food and Drug Administration approval in September 2025 with interchangeable designation.</p> <p>Bosaya serves as a biosimilar to Prolia for treating osteoporosis, while Aukelso functions as a biosimilar to Xgeva for bone complications associated with cancer. Both products are available nationwide through specialty pharmacies and healthcare providers by prescription.</p> <p>The interchangeable designation allows pharmacy-level substitution in accordance with state laws. Denosumab products generated approximately $5 billion in U.S. sales in 2024, according to http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html Tue, 07 Apr 2026 09:31:06 -0400 532523 A.06822034 A.25841868 A.30142833 BIOCON O.00003102 O.01260902 O.20026344 O.26741422 http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html <p>Biocon Limited (BSE: 532523, NSE: BIOCON) announced the commercial launch of two denosumab biosimilar products in the United States. The company launched Bosaya and Aukelso, both denosumab-kyqq products, following U.S. Food and Drug Administration approval in September 2025 with interchangeable designation.</p> <p>Bosaya serves as a biosimilar to Prolia for treating osteoporosis, while Aukelso functions as a biosimilar to Xgeva for bone complications associated with cancer. Both products are available nationwide through specialty pharmacies and healthcare providers by prescription.</p> <p>The interchangeable designation allows pharmacy-level substitution in accordance with state laws. Denosumab products generated approximately $5 billion in U.S. sales in 2024, according to http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html Tue, 07 Apr 2026 09:31:06 -0400 532523 A.06822034 A.25841868 A.30142833 BIOCON O.00003102 O.01260902 O.20026344 O.26741422 http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html <p>Biocon Limited (BSE: 532523, NSE: BIOCON) announced the commercial launch of two denosumab biosimilar products in the United States. The company launched Bosaya and Aukelso, both denosumab-kyqq products, following U.S. Food and Drug Administration approval in September 2025 with interchangeable designation.</p> <p>Bosaya serves as a biosimilar to Prolia for treating osteoporosis, while Aukelso functions as a biosimilar to Xgeva for bone complications associated with cancer. Both products are available nationwide through specialty pharmacies and healthcare providers by prescription.</p> <p>The interchangeable designation allows pharmacy-level substitution in accordance with state laws. Denosumab products generated approximately $5 billion in U.S. sales in 2024, according to http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html Tue, 07 Apr 2026 09:31:06 -0400 532523 A.06822034 A.25841868 A.30142833 BIOCON O.00003102 O.01260902 O.20026344 O.26741422 http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html <p>Biocon Limited (BSE: 532523, NSE: BIOCON) announced the commercial launch of two denosumab biosimilar products in the United States. The company launched Bosaya and Aukelso, both denosumab-kyqq products, following U.S. Food and Drug Administration approval in September 2025 with interchangeable designation.</p> <p>Bosaya serves as a biosimilar to Prolia for treating osteoporosis, while Aukelso functions as a biosimilar to Xgeva for bone complications associated with cancer. Both products are available nationwide through specialty pharmacies and healthcare providers by prescription.</p> <p>The interchangeable designation allows pharmacy-level substitution in accordance with state laws. Denosumab products generated approximately $5 billion in U.S. sales in 2024, according to http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html Tue, 07 Apr 2026 09:31:06 -0400 532523 A.06822034 A.25841868 A.30142833 BIOCON O.00003102 O.01260902 O.20026344 O.26741422 http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html <p>Biocon Limited (BSE: 532523, NSE: BIOCON) announced the commercial launch of two denosumab biosimilar products in the United States. The company launched Bosaya and Aukelso, both denosumab-kyqq products, following U.S. Food and Drug Administration approval in September 2025 with interchangeable designation.</p> <p>Bosaya serves as a biosimilar to Prolia for treating osteoporosis, while Aukelso functions as a biosimilar to Xgeva for bone complications associated with cancer. Both products are available nationwide through specialty pharmacies and healthcare providers by prescription.</p> <p>The interchangeable designation allows pharmacy-level substitution in accordance with state laws. Denosumab products generated approximately $5 billion in U.S. sales in 2024, according to http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html Tue, 07 Apr 2026 09:31:06 -0400 532523 A.06822034 A.25841868 A.30142833 BIOCON O.00003102 O.01260902 O.20026344 O.26741422 http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html <p>Biocon Limited (BSE: 532523, NSE: BIOCON) announced the commercial launch of two denosumab biosimilar products in the United States. The company launched Bosaya and Aukelso, both denosumab-kyqq products, following U.S. Food and Drug Administration approval in September 2025 with interchangeable designation.</p> <p>Bosaya serves as a biosimilar to Prolia for treating osteoporosis, while Aukelso functions as a biosimilar to Xgeva for bone complications associated with cancer. Both products are available nationwide through specialty pharmacies and healthcare providers by prescription.</p> <p>The interchangeable designation allows pharmacy-level substitution in accordance with state laws. Denosumab products generated approximately $5 billion in U.S. sales in 2024, according to http://www.streetinsider.com/Corporate+News/Biocon+launches+denosumab+biosimilars+in+US+market/26279547.html Tue, 07 Apr 2026 09:31:06 -0400 532523 A.06822034 A.25841868 A.30142833 BIOCON O.00003102 O.01260902 O.20026344 O.26741422 http://www.streetinsider.com/Press+Releases/Biocon+Announces+U.S.+Commercial+Launch+of+Bosaya%E2%84%A2+and+Aukelso%E2%84%A2%2C+Denosumab+Biosimilars/26279542.html <ul class="bwlistdisc"> <li> Bosaya™ and Aukelso™ (both denosumab-kyqq products) now available in the United States, following U.S. FDA approval in September 2025 with an interchangeable designation </li> <li> Potential benefit to the estimated 10 million adults with osteoporosis and over 330,000 patients annually with bone metastasis, a common complication of advanced cancer </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the commercial launch of <b>Bosaya™ (denosumab-kyqq)</b> and <b>Aukelso™ (denosumab-kyqq)</b> in the United States. Bosaya™ (biosimilar to <i>Prolia®</i>) and Aukelso™ (biosimilar to <i>Xgeva®</i>) are now available by prescription nationwide through specialty pharmacies and http://www.streetinsider.com/Press+Releases/Biocon+Announces+U.S.+Commercial+Launch+of+Bosaya%E2%84%A2+and+Aukelso%E2%84%A2%2C+Denosumab+Biosimilars/26279542.html Tue, 07 Apr 2026 08:05:00 -0400 532523 A.06822034 A.25841868 A.30142833 BIOCON O.00003102 O.01260902 O.20026344 O.26741422 http://www.streetinsider.com/Press+Releases/Biocon+Announces+U.S.+Commercial+Launch+of+Bosaya%E2%84%A2+and+Aukelso%E2%84%A2%2C+Denosumab+Biosimilars/26279542.html <ul class="bwlistdisc"> <li> Bosaya™ and Aukelso™ (both denosumab-kyqq products) now available in the United States, following U.S. FDA approval in September 2025 with an interchangeable designation </li> <li> Potential benefit to the estimated 10 million adults with osteoporosis and over 330,000 patients annually with bone metastasis, a common complication of advanced cancer </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the commercial launch of <b>Bosaya™ (denosumab-kyqq)</b> and <b>Aukelso™ (denosumab-kyqq)</b> in the United States. Bosaya™ (biosimilar to <i>Prolia®</i>) and Aukelso™ (biosimilar to <i>Xgeva®</i>) are now available by prescription nationwide through specialty pharmacies and http://www.streetinsider.com/Press+Releases/Biocon+Announces+U.S.+Commercial+Launch+of+Bosaya%E2%84%A2+and+Aukelso%E2%84%A2%2C+Denosumab+Biosimilars/26279542.html Tue, 07 Apr 2026 08:05:00 -0400 532523 A.06822034 A.25841868 A.30142833 BIOCON O.00003102 O.01260902 O.20026344 O.26741422